Investigation announced for Investors in NASDAQ: OMER shares over possible Wrongdoing at Omeros Corporation

An investigation was announced over potential breaches of fiduciary duties by certain officers and directors at Omeros Corporation.

Investors who purchased shares of Omeros Corporation (NASDAQ: OMER) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

The investigation by a law firm concerns whether certain Omeros Corporation directors breached their fiduciary duties and caused damage to the company and its shareholders.

Seattle, WA based Omeros Corporation, a commercial-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, disorders of the central nervous system (CNS), and immune-related diseases. Omeros Corporation reported that its annual Total Revenue declined from $111.8 million in 2019 to $73.81 million in 2020, and that its Net Loss increased from $84.48 million in 2019 to $138.06 million in 2020.

On October 1, 2021, Omeros Corporation (NASDAQ: OMER) announced that the U.S. Food and Drug Administration ("FDA") had identified deficiencies with the Company’s Biologics License Application for its drug candidate narsoplimab in the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA), which "preclude discussion of labeling and post-marketing requirements/commitments at this time." Though the "FDA did not provide specific details of the deficiencies in its notification[,]" the Company stated that it "does not currently expect any resolution to occur by the October 17, 2021 target action date under the Prescription Drug User Fee Act (PDUFA)."

Shares of Omeros Corporation (NASDAQ: OMER) declined from $16.30 per share on September 24, 2021, to $6.52 per share on October 8, 2021.

Those who purchased shares of Omeros Corporation (NASDAQ: OMER) have certain options and should contact the Shareholders Foundation.

Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.